These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33222634)

  • 1. Dose-finding design and benchmark for a right censored endpoint.
    Andrillon A; Chevret S; Lee SM; Biard L
    J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
    BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
    North B; Kocher HM; Sasieni P
    BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
    Andrillon A; Biard L; Lee SM
    J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
    Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
    Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.
    Yin G; Yang Z
    Contemp Clin Trials Commun; 2020 Sep; 19():100650. PubMed ID: 32875142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
    Yin Z; Mander AP; de Bono JS; Zheng H; Yap C
    JCO Precis Oncol; 2024 Jan; 8():e2300441. PubMed ID: 38181316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding designs for cumulative toxicities using multiple constraints.
    Lee SM; Ursino M; Cheung YK; Zohar S
    Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simulation study of approaches for handling disease progression in dose-finding clinical trials.
    Biard L; Cheng B; Manji GA; Lee SM
    J Biopharm Stat; 2021 Mar; 31(2):156-167. PubMed ID: 32931360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes.
    Alger E; Lee SM; Cheung YK; Yap C
    ESMO Open; 2024 Jul; 9(7):103626. PubMed ID: 38968929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring late-onset toxicities in phase I trials using predicted risks.
    Bekele BN; Ji Y; Shen Y; Thall PF
    Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.